117 related articles for article (PubMed ID: 15334065)
1. Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts.
Chen CM; Chang JL; Behringer RR
Oncogene; 2004 Oct; 23(46):7722-5. PubMed ID: 15334065
[TBL] [Abstract][Full Text] [Related]
2. Granulosa cell tumorigenesis in genetically hypogonadal-immunodeficient mice grafted with ovaries from tumor-susceptible donors.
Beamer WG; Shultz KL; Tennent BJ; Shultz LD
Cancer Res; 1993 Aug; 53(16):3741-6. PubMed ID: 8339285
[TBL] [Abstract][Full Text] [Related]
3. Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germ line p53 mutation.
Wang Y; Zhang Z; Lu Y; Yao R; Jia D; Wen W; LaRegina M; Crist K; Lubet R; You M
Mol Cancer Res; 2008 Jan; 6(1):99-109. PubMed ID: 18234966
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
5. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
6. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer.
Kohler MF; Kerns BJ; Humphrey PA; Marks JR; Bast RC; Berchuck A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):643-50. PubMed ID: 8469448
[TBL] [Abstract][Full Text] [Related]
7. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
[TBL] [Abstract][Full Text] [Related]
8. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
10. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.
Jerry DJ; Kittrell FS; Kuperwasser C; Laucirica R; Dickinson ES; Bonilla PJ; Butel JS; Medina D
Oncogene; 2000 Feb; 19(8):1052-8. PubMed ID: 10713689
[TBL] [Abstract][Full Text] [Related]
11. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.
Flesken-Nikitin A; Choi KC; Eng JP; Shmidt EN; Nikitin AY
Cancer Res; 2003 Jul; 63(13):3459-63. PubMed ID: 12839925
[TBL] [Abstract][Full Text] [Related]
12. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis.
Kiaris H; Chatzistamou I; Trimis G; Frangou-Plemmenou M; Pafiti-Kondi A; Kalofoutis A
Cancer Res; 2005 Mar; 65(5):1627-30. PubMed ID: 15753354
[TBL] [Abstract][Full Text] [Related]
13. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
14. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis.
Buller RE; Sood A; Fullenkamp C; Sorosky J; Powills K; Anderson B
Cancer Gene Ther; 1997; 4(4):239-45. PubMed ID: 9253509
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes.
Sasaki R; Narisawa-Saito M; Yugawa T; Fujita M; Tashiro H; Katabuchi H; Kiyono T
Carcinogenesis; 2009 Mar; 30(3):423-31. PubMed ID: 19126650
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.
Corney DC; Flesken-Nikitin A; Godwin AK; Wang W; Nikitin AY
Cancer Res; 2007 Sep; 67(18):8433-8. PubMed ID: 17823410
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
20. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
